Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial

Article summary

Longeveron reported updated results from its ELPIS II Phase 2b clinical trial for laromestrocel in infants with hypoplastic left heart syndrome (HLHS), noting that while the primary endpoint was not met, the therapy showed significant results in reducing major adverse cardiac events.